FDA approves Emergency Use Authorization for COVID-19 drug combo
UPDATED 6:45 PM PT – Friday, November 20, 2020
The U.S. Food and Drug Administration granted an Emergency Use Authorization for a coronavirus drug combination to treat moderate and seriously ill patients.
FDA Commissioner Stephen M. Hahn (M.D.) said this action demonstrates the agency’s steadfast efforts to make potential coronavirus treatments available in a timely manner.
On Thursday, the FDA gave approval for the mix of ‘remdesevir’ and rheumatoid arthritis drug ‘baricitinib.’ This came after studies found the drug combination shortened the recovery time for COVID-19 to about a week.
As of today, 289 tests are authorized by the FDA under EUAs; these include 224 molecular tests, 58 antibody tests, and 7 antigen tests.
— U.S. FDA (@US_FDA) November 21, 2020
According to a double-blind trial, the combination also increased the chances of survival by 35 percent when compared to patients that only took ‘remdesivir.’
The FDA has granted emergency use authorization for the arthritis drug baricitinib to be used in combination with remdesivir to treat hospitalized adults and children with suspected or confirmed COVID-19. https://t.co/GVSGz9mdRx pic.twitter.com/esKvNvIg8x
— WebMD (@WebMD) November 20, 2020